FAQs

CVRx is a leader in innovative medical technologies that address unmet needs in cardiovascular diseases with safe and effective therapies that harness and harmonize the body’s natural systems. We are dedicated to improving patient outcomes, quality of life, and overall cardiovascular health via novel baroreceptor neuromodulation therapy.

Our product is Barostim - Baroreflex Activation Therapy (BAT). Barostim is the first medical technology approved by the FDA that uses neuromodulation - the power of the brain and nervous system - to improve the symptoms of patients with systolic heart failure (HF). Barostim is delivered by the Barostim NEO™ Generator, an implantable device that uses our patented technology to send electrical pulses to baroreceptors located in the wall of the carotid artery via a small stimulation lead. Baroreceptors trigger the body’s baroreflex which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of HF. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in HF patients in the US. It has also received the CE Mark for HF and resistant hypertension in the European Economic Area.